Detalles de la búsqueda
1.
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.
Circulation
; 147(16): 1192-1203, 2023 04 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36779348
2.
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
Circulation
; 146(15): 1109-1119, 2022 10 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36031810
3.
Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a).
Cardiovasc Drugs Ther
; 2022 Nov 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36435949
4.
Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
Cardiovasc Diabetol
; 20(1): 94, 2021 04 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-33941192
5.
Pharmacokinetic/pharmacodynamic and safety study of a single dose of evolocumab 140 mg in healthy Chinese subjects.
Int J Clin Pharmacol Ther
; 58(10): 557-564, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32729822
6.
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.
Diabetologia
; 62(6): 948-958, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30953107
7.
Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial.
Diabetes Obes Metab
; 21(6): 1455-1463, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30821053
8.
Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial.
Diabetes Obes Metab
; 21(6): 1464-1473, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30851062
9.
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
Lancet
; 388(10062): 2895-2903, 2016 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27914656
10.
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
N Engl J Med
; 370(19): 1809-19, 2014 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24678979
11.
Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.
Circ Res
; 117(8): 731-41, 2015 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-26228031
12.
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.
Diabetes Obes Metab
; 19(1): 98-107, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27619750
13.
Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects.
Int J Clin Pharmacol Ther
; 54(3): 217-27, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26709596
14.
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease.
J Am Coll Cardiol
; 83(6): 652-664, 2024 Feb 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38325990
15.
Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO Randomized Clinical Trial.
Cardiol Ther
; 12(2): 341-359, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36802321
16.
Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Anticancer Drugs
; 23(3): 335-41, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22123335
17.
Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials.
J Clin Lipidol
; 16(4): 538-543, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35760720
18.
Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies.
J Am Heart Assoc
; 10(1): e016839, 2021 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33325247
19.
Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.
J Am Heart Assoc
; 9(5): e014129, 2020 03 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32114889
20.
A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects.
Clin Pharmacol
; 11: 145-153, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31695519